

<ul style="list-style-type: none"><li>• Electronic copy is controlled under document control procedure. Hard copy is uncontrolled &amp; under responsibility of beholder.</li><li>• It is allowed ONLY to access and keep this document with who issued, who is responsible and to whom it is applicable.</li><li>• Information security code: <input checked="" type="checkbox"/> Open <input type="checkbox"/> Shared -Confidential <input type="checkbox"/> Shared-Sensitive <input type="checkbox"/> Shared-Secret</li></ul>	<ul style="list-style-type: none"><li>• النسخة الإلكترونية هي النسخة المضبوطة وفق إجراء ضبط الوثائق. النسخ الورقية غير مضبوطة وتقع على مسؤولية حاملها.</li><li>• يسمح بالوصول والاحتفاظ بهذه الوثيقة مع مصدرها أو مع المسؤول عن تطبيقها أو مع المطبق عليهم.</li><li>• تصنيف امن المعلومات: <input checked="" type="checkbox"/> بيانات مفتوحة <input type="checkbox"/> شارك -سري <input type="checkbox"/> مشارك -حساس <input type="checkbox"/> مشارك -سري</li></ul>
--	--

# STANDARDS FOR SARS- COV-2 TESTING

## Version 5.2

Health Policies and Standards Department

Health Regulation Sector (2021)

## INTRODUCTION

Health Regulation Sector (HRS) forms an integral part of Dubai Health Authority (DHA) and is mandated by DHA Law No. (6) of 2018 to undertake several functions including but not limited to:

- Developing regulation, policy, standards, guidelines to improve quality and patient safety and promote the growth and development of the health sector.
- Licensure and inspection of health facilities as well as healthcare professionals and ensuring compliance to best practice.
- Managing patient complaints and assuring patient and physician rights are upheld.
- Managing health advertisement and marketing of healthcare products.
- Governing the use of Narcotics, Controlled and Semi-Controlled Medications.
- Strengthening health tourism and assuring ongoing growth.
- Assuring management of health informatics, e-health and promoting innovation.

The Standards for SARS-CoV-2 Testing aims to fulfil the following overarching DHA Strategic Objectives and Program within the Dubai Health Strategy (2016–2021):

- **Objective 1:** Position Dubai as a global medical destination by introducing a value-based, comprehensive, integrated and high-quality service delivery system.
- **Objective 2:** Direct resources to ensure happy, healthy and safe environment for Dubai population.

**Strategic Program 10:** Excellence & Quality, which promotes excellence in healthcare service delivery in Dubai while enhancing patient happiness, experience, satisfaction and trust.

## ACKNOWLEDGMENT

The Health Policy and Standards Department (HPSD) developed this Standard in collaboration with Subject Matter Experts and would like to acknowledge and thank these health professionals for their dedication toward improving quality and safety of healthcare services in the Emirate of Dubai.

### Health Regulation Sector

### Dubai Health Authority

## TABLE OF CONTENTS

INTRODUCTION .....	2
ACKNOWLEDGMENT .....	3
EXECUTIVE SUMMARY .....	6
DEFINITIONS .....	7
ABBREVIATIONS .....	8
1. BACKGROUND .....	9
2. SCOPE.....	9
3. PURPOSE .....	9
4. APPLICABILITY .....	9
5. STANDARD ONE: REGISTRATION AND APPROVAL REQUIREMENTS .....	10
6. STANDARD TWO: TESTING CRITERIA .....	11
7. STANDARD THREE: SAMPLE COLLECTION .....	12
8. STANDARD FOUR: SALIVA SAMPLE COLLECTION.....	15
9. STANDARD FIVE: SAMPLE STORAGE .....	16
10. STANDARD SIX: SAMPLE TRANSPORT .....	16
11. STANDARD SEVEN: SAMPLE PROCESSING .....	17
12. STANDARD EIGHT: INTERPRETATION OF RESULT .....	19
13. STANDARD NINE: RESULT REPORTING .....	19
14. STANDARD TEN: NUCLEIC ACID AMPLIFICATION FOR DETECTION OF SARS-COV2 AS POINT OF CARE TEST (POCT) .....	20
15. STANDARD ELEVEN: ANTIBODY TESTING .....	21
16. STANDARD TWELVE: INFECTIOUS WASTE MANAGEMENT .....	23
17. STANDARD THIRTEEN: SAMPLE RETENTION .....	23
REFERENCES .....	24
APPENDICES.....	27

<b>APPENDIX 1: TESTING HEALTH FACILITY REGISTRATION TEMPLATE (SAMPLE COLLECTION).....</b>	<b>27</b>
<b>APPENDIX 2: CLINICAL LABS REGISTRATION TEMPLATE.....</b>	<b>29</b>
<b>APPENDIX 3: DRIVE-THROUGH COVID-19 TESTING REGISTRATION TEMPLATE .....</b>	<b>31</b>
<b>APPENDIX 4: COVID-19 TESTING TENT REGISTRATION TEMPLATE .....</b>	<b>34</b>
<b>APPENDIX 5: APPROVED COVID-19 LABS .....</b>	<b>36</b>
<b>APPENDIX 6: TESTING PRIORITY .....</b>	<b>37</b>
<b>APPENDIX 7: COVID-19 SAMPLE LABELLING .....</b>	<b>38</b>
<b>APPENDIX 8: COVID-19 FALSE POSITIVE DUE TO CARRY-OVER CONTAMINATION .....</b>	<b>40</b>
<b>APPENDIX 9: AUTHORIZED RT-PCR KITS FOR SARS-COV2 BY DHA.....</b>	<b>42</b>
<b>APPENDIX 10: INTERPRETATION OF COVID-19 RT-PCR TEST .....</b>	<b>43</b>
<b>APPENDIX 11: SMS TEMPLATE FOR PCR TEST RESULTS.....</b>	<b>45</b>
<b>APPENDIX 12: CALL LOG REPORT TEMPLATE.....</b>	<b>46</b>
<b>APPENDIX 13: NUCLEIC ACID AMPLIFICATION AS POINT OF CARE TEST (POCT) FOR SARS-COV 2 TEST AT EMERGENCY DEPARTMENT OF HOSPITALS ALGORITHM.....</b>	<b>47</b>
<b>APPENDIX 14: DISCLAIMER STATEMENT IN SEROLOGICAL TESTING FOR COVID-19.....</b>	<b>48</b>

## EXECUTIVE SUMMARY

This is edition 5.2 of the Standards for SARS-CoV-2 Testing in health facilities. This document is based on current knowledge of the situation in the UAE and across the globe; it is aligned with current international guidelines and circulars issued by DHA related to the subject. The document aims to ensure public and patient health protection and to ensure efficiency and integrity of testing services applied to handle negative and positive cases of COVID-19, in all DHA licensed health facilities providing SARS-CoV-2 Testing services. DHA will update these Standards as new information becomes available.

The key updates on Version 5.2 are set out below:

- Registration and Approval Requirements. (Page 10)
- Sample Collection. (Page 12)
- Addition of nasal swab requirements. (pages 13-14)
- Updates to the Saliva Sample Collection Standards. (page 15)
- Updates on sample processing. (page 19)
- Updates on Antibody Testing. (Page 22).
- Appendix (2) Clinical Labs Registration Template. (Page 29)
- Appendix (5) Approved COVID-19 Labs. (page 36).

## DEFINITIONS

**Confirmed case:** A person meeting the clinical and laboratory diagnostic criteria for COVID-19 with positive SARS-CoV-2 PCR test by an approved laboratory.

**Health Facility:** A DHA licensed entity that is authorised to provide medical services whether its owner or manager is an individual or an organization.

**Healthcare Professional:** is a natural person who is authorized and licensed by the DHA to practice any of the healthcare professions in the Emirate.

**Isolation:** is separation of patients and/or staff into a secluded area or room for infection control purposes. Isolation may include self-isolation in a room, home or residential institution.

**Quarantine:** Separation and restriction of movement of patients or people who are exposed to a contagious disease to determine if they have been exposed or become sick.

**Suspected COVID-19:** Patient who presents upper or lower respiratory symptoms with or without fever ( $\geq 37.5^{\circ}\text{C}$ ) AND fulfilling any one of the following criteria:

- International travel history during the 14 days prior to symptom onset.
- Been in contact with a confirmed COVID-19 case within 14 days.
- Residing in a community setting where COVID-19 cases have been detected **OR**
- Presence of influenza-like symptoms without history of travel or known possible exposure.

## ABBREVIATIONS

<b>AN</b>	:	Assistant Nurse
<b>CAP</b>	:	College of American Pathologists
<b>COVID</b>	:	Corona Virus Disease
<b>CP</b>	:	Convalescent Plasma
<b>DHA</b>	:	Dubai Health Authority
<b>EUA</b>	:	Emergency Use Authorization
<b>HCP</b>	:	Health Care Personnel
<b>HPSD</b>	:	Health Policies and Standards Department
<b>HRS</b>	:	Health Regulation Sector
<b>ISO</b>	:	International Organization for Standardization
<b>PCR</b>	:	Polymerase Chain Reaction
<b>POCT</b>	:	Point of Care Testing
<b>PPE</b>	:	Personal Protective Equipment
<b>RN</b>	:	Registered Nurse
<b>RT-PCR</b>	:	Reverse Transcription Polymerase Chain Reaction
<b>SARS</b>	:	Severe Acute Respiratory Syndrome
<b>VTM</b>	:	Viral Transport Media



## 1. BACKGROUND

As part of the continuous efforts to monitor healthcare system's response to the Corona Virus Disease (COVID-19), and to ensure public health protection and efficiency of procedures of diagnosing the disease and proper utilization of the resources, DHA has set out the following requirements regarding COVID-19 Screening and Testing. The Standard will be updated by DHA periodically based on changes in National Standards and federal decisions. All relevant DHA Licensed Health Facilities are required to adhere to the requirements within the document to avoid non-compliance.

## 2. SCOPE

2.1. SARS-CoV-2 Testing services in DHA licensed health facilities.

## 3. PURPOSE

- 3.1. To assure provision of the highest levels of safety and quality in SARS-CoV-2 Testing services in DHA licensed health facilities.
- 3.2. To ensure patients who are tested for SARS-CoV-2 are provided with timely, reliable and valid results.
- 3.3. To prevent the use of non-approved DHA laboratories from testing and issuing results.
- 3.4. To reject COVID-19 test results from non-approved DHA laboratories and impose disciplinary actions.

## 4. APPLICABILITY

4.1. DHA licensed health facilities providing SARS-CoV-2 Testing services.

## 5. STANDARD ONE: REGISTRATION AND APPROVAL REQUIREMENTS

5.1. Swab collection services for COVID-19 are limited to below healthcare facilities following approval by DHA:

5.1.1. Hospitals.

5.1.2. Day Surgery Centres (DSC).

5.1.3. Outpatient Clinics.

5.1.4. Clinical Laboratories approved for COVID-19 testing, with dedicated area for sample collection.

5.1.5. Home Healthcare Providers–Standalone or service licensed under other DHA licensed health facilities.

5.1.6. School Clinics.

5.2. SARS-CoV-2 Test processing services are limited to below healthcare facilities following approval by DHA:

5.2.1. DHA Clinical Laboratories.

5.2.2. Standalone Clinical Laboratories.

5.2.3. Clinical Laboratories within Hospitals.

5.3. Healthcare facilities and Clinical Laboratories seeking approval should:

5.3.1. Submit a proposal for DHA (**Appendices 1, 2, 3 and 4**), through Sheryan facility account.

5.3.2. Submit online application through Sheryan, for 'COVID swabbing' add-on.

5.3.3. Comply with DHA inspection requirements.

5.3.4. Register in HASANA platform and acquire the necessary training.

- 5.3.5. Engage in regular inter-laboratory comparison with DHA as required.
- 5.4. Clinical Laboratories should integrate their Laboratory Information System with HASANA platform.
- 5.5. List of approved laboratories for COVID-19 testing as of (December 2020) can be found in (**Appendix 5**).
- 5.6. Swab collecting facilities should have in place a valid contract with a DHA approved and HASANA integrated clinical laboratory.
- 5.6.1. Samples should not be sent to clinical labs outside the emirate of Dubai after 14th June 2020.
- 5.6.2. Secondary and tertiary labs should be DHA approved SARS-CoV-2 Testing Laboratories.

## 6. STANDARD TWO: TESTING CRITERIA

- 6.1. COVID-19 testing should only be requested by a DHA licensed physician in accordance to the National Clinical Guidelines and based on the attached priority testing criteria (**Appendix 6**).
- 6.1.1. DHA and the COVID-19 Command and Control Centre should update testing criteria regularly.
- 6.1.2. For suspected COVID-19 cases, the treating physician should give clear and comprehensive instructions to the patient regarding self-quarantine until the results reported.

- 6.1.3. It is the responsibility of the treating physician to report the test result to the patients and to provide the necessary information and guidance based on the national guidelines.
- 6.2. All health facilities should comply with the fixed service price for testing COVID-19 as announced by DHA through circulars and refrain from adding any additional fees for delivery of the test result including but not limited to phone, call, text, VIP or expedite services.
- 6.3. Testing Laboratories should implement molecular testing Polymerase Chain Reaction (PCR) for diagnosis of COVID-19 and Reverse Transcription Polymerase Chain Reaction (RT-PCR) as the approved testing methodology for detection of SARS-COV-2 virus.

## 7. **STANDARD THREE: SAMPLE COLLECTION**

- 7.1. Health facilities should gain approval from DHA prior to starting sample collection services as above.
- 7.2. Swab collecting facilities must adhere to all DHA regulations relevant to the facility category.
- 7.3. Health facilities should have a dedicated room for swab collection with infection control setup including, but not limited to:
- 7.3.1. Air purification system.
  - 7.3.2. Negative pressure or good air circulation.
  - 7.3.3. Hand washing sink.

- 7.4. Swabs collection conducted at non-healthcare setup should comply with the below requirements:
  - 7.4.1. Obtain prior approval from DHA.
  - 7.4.2. Ensure availability of an online pre-booking appointment system.
  - 7.4.3. Ensure sample collection in an outdoor space or well ventilated area.
  - 7.4.4. Follow infection control measures.
  - 7.4.5. Ensure accurate and timely patient data entry.
  - 7.4.6. Ensure following sample storage and transport measures as listed in this standard.
- 7.5. Swabs should be collected under aseptic conditions and should be placed immediately into sterile transport tube of 2-3 ml Viral Transport Media (VTM).
- 7.6. VTM should be validated with each Extraction platform and Each PCR kit to exclude the possibility of inhibitors to extraction/amplification platforms.
- 7.7. HF shall ensure that nasal sample fulfil the below requirements:
  - 7.7.1. Brand name
  - 7.7.2. Manufacturer name and address
  - 7.7.3. CE Marking
- 7.8. HF should maintain the following documents for nasal sample swabs:
  - 7.8.1. The manufacturer's EU declaration of conformity
  - 7.8.2. The CE sterility certificate

- 7.9. Healthcare professionals collecting the specimens should follow infection control measures and use recommended Personal Protective Equipment (PPE) (N95, facemask, eye protection, gloves and a gown).
- 7.10. It is preferable for initial diagnostic testing/specimen for SARS-CoV-2 to be taken from upper respiratory (Nasopharyngeal or Oropharyngeal) sites.
- 7.11. Testing lower respiratory tract specimens (Broncho alveolar lavage) are an option for patients with productive cough or receiving invasive mechanical ventilation.
- 7.12. Only trained and privileged licensed healthcare professionals in an appropriate setting should collect COVID-19 swabs.
- 7.12.1. Swab collection training videos can be accessed through [DHA Medical Education Department](#).
- 7.12.2. Training logs and privileges by the medical director shall be maintained.
- 7.13. DHA Approved health facilities should ensure all patient details are filled accurately and on timely manner in HASANA System<sup>1</sup> as per [Communicable Disease Notification Policy](#) timeline.
- 7.14. Health facilities collecting swabs from patients should ensure the type of swab used corresponds to the testing devices of the approved lab processing the test.
- 7.15. Health facilities should provide the HASANA client ID to the processing lab to ensure correct test result entry.
- 7.16. Health facilities should update swab collection data in Sheryan system daily, before 12am.

---

<sup>1</sup> For HASANA related inquiries contact: [HasanaHelpdesk@dha.gov.ae](mailto:HasanaHelpdesk@dha.gov.ae)

## 8. STANDARD FOUR: SALIVA SAMPLE COLLECTION

- 8.1. Saliva samples can be collected by all approved facilities for sample collection.
- 8.2. Saliva samples should only be collected as a non-invasive alternative sample for RT-PCR in the below conditions:
  - 8.2.1. Screening of asymptomatic children up to 17 years of age.
  - 8.2.2. Children who are likely to be uncooperative for nasopharyngeal swab sampling.
  - 8.2.3. Screening for People of Determination.
  - 8.2.4. Samples should be collected under supervision of a trained DHA licensed healthcare professional.
- 8.3. Saliva samples should be taken following the below steps:
  - 8.3.1. Patient must be dry fasting at least thirty (30) minutes to one (1) hour before collection of saliva.
  - 8.3.2. Saliva must be pooled in mouth for 1-2 minutes prior to collection, and then gently spit 1-2 mL into the sterile, leak-proof, screw-cap sputum collection cup or a sterile dry container.
  - 8.3.3. Close container tightly, seal with para film and place in hazardous bag.
  - 8.3.4. Send the sample to an approved DHA Laboratory for SARS-COV-2 Test Processing (**Appendix 5**).
- 8.4. DHA Approved health facilities should ensure all patient details are filled accurately and on timely manner in HASANA System<sup>2</sup> as per [Communicable Disease Notification Policy](#) timeline.

---

<sup>2</sup> For HASANA related inquiries contact: [HasanaHelpdesk@dha.gov.ae](mailto:HasanaHelpdesk@dha.gov.ae)

- 8.5. Health facilities should provide the HASANA client ID to the processing lab to ensure correct test result entry.
- 8.6. Health facilities should update sample collection data in Sheryan system daily, before 12am.

## 9. STANDARD FIVE: SAMPLE STORAGE

- 9.1. Secure designated space with an access restriction, near a hand-washing basin must be provided for safe storage of Laboratory specimens.
- 9.2. Labelling the collected sample as a biohazard.
- 9.3. The collected swab along with viral tube media should be collected under aseptic condition and stored immediately in a separate fridge in a temperature of 2-8°C or stored in an icebox until it is delivered to the testing laboratory as soon as possible with the availability of thermometer to register the temperature.
- 9.4. The specimens should be stored in a (-20) freezer where there is a delay of over 12 hours in specimen transport.

## 10. STANDARD SIX: SAMPLE TRANSPORT

- 10.1. All materials transported within and between laboratories should be placed in a secondary packaging, to minimize the potential for breakage or a spill.
- 10.2. Transport of COVID-19 samples should be through cold chain logistics.
- 10.3. Laboratory specimens must be collected, transported and handled safely to ensure that no risk of infection is transferred to the personnel involved.
  - 10.3.1. Samples should be transported on timely basis, avoiding delay and batching.



a. In case of delay, proper cold chain storage and transport procedure should be maintained by the collecting health facility and the testing Laboratory should be notified about the delay.

10.4. Samples should be dispatched within two (2) hours from collection time using double packaging system.

10.5. Samples should be labelled as detailed and shown in (**Appendix 7**).

10.6. Bio-hazardous materials precautions should be adhered to by transport personnel and couriers during transport of samples.

10.6.1. Transport personnel or couriers should be trained by the collecting health facility on safe handling practices and infection control procedures.

10.6.2. All transport personnel are required to wear PPE at all times.

## 11. STANDARD SEVEN: SAMPLE PROCESSING

11.1. Clinical Laboratories shall fulfil the facility design requirements as outlined in the [Health Facility Design Guidelines](#).

11.2. Clinical Laboratories should seek approval from HRS prior to processing any SARS-CoV-2 related tests.

11.3. Clinical Laboratories should process SARS-CoV-2 test types as per the approval received from HRS.

11.4. The gold standard for diagnosis of COVID-19 is RT-PCR using SARS-CoV-2 kits.

11.5. Testing Laboratories should ensure that the received samples are for clients registered on HASANA prior to processing.

- 11.6. Laboratories should refrain from adding up samples from a group of patients (Samples Pooling) before RNA extraction or before PCR runs.
- 11.7. Laboratories should follow the protocol in **Appendix 8** to ensure quality measurement steps to prevent laboratory environment and carry over contamination.
- 11.8. Testing laboratory should implement one or two RNA extraction platforms along with quality control for RNA extraction.
- 11.9. Testing laboratories providing COVID-19 testing services shall use any of DHA approved SARS-CoV-2 kits listed in (**Appendix 9**).
- 11.10. Testing laboratories should validate each new PCR kit for sensitivity (lower detection limit) and specificity to avoid false results and be able to detect low viral load. The new PCR kit should allow testing laboratories to report detected, not detected and presumptive positive (low viral load or single gene).
- 11.11. Records of validation should be kept at the lab for DHA audit and inspection.
- 11.12. Testing lab that is using another type of kit; not included in the list should contact HRS-DHA for assessment and validation (**Appendix 9**).
- 11.13. Testing laboratory should use two different RT-PCR kits. Each RT-PCR kit should cover at least two or more of the following genes (ORF1ab/RdRp, N, S, E, M).
- 11.14. If one gene is detected with one RT- PCR kit then a second test should be done and the results should be interpreted as per NCEMA guidelines (**Appendix 10**).
- 11.15. Testing results must be issued within a maximum period of 24 hours from the date of swab collection.

11.16. Approved labs must ensure they perform the required quality control for RNA extraction and RT-PCR protocols as per manufacture's guidelines and comply with required preventive maintenance and calibration of lab equipment.

11.17. De-isolation measures should be followed as per the National Guidelines for the Management of COVID-19.

## 12. STANDARD EIGHT: INTERPRETATION OF RESULT

12.1. Interpretation of results should be correlated with patient history and clinical presentation.

12.2. Interpretation of results should align with the published NCEMA guidelines for interpretation of PCR test.

12.3. Test for SARS-CoV-2 result can be one of the following:

12.3.1. Detected (positive for SARS-CoV-2)

12.3.2. Not Detected (Negative for SARS-CoV-2)

12.3.3. Presumptive positive (only one of multiple gene is isolated or a low viral load is possible)

a. Sample should be repeated in 72 hours with clinical correlation.

## 13. STANDARD NINE: RESULT REPORTING

13.1. Testing results should be entered in HASANA immediately by the processing lab through integration.

13.2. Facilities are required to inform their patients of COVID-19 test result.

13.2.1. Negative test results should be reported to the patient and/or guardian via phone call and/or mobile text message (SMS) within 24hrs of result interpretation.

13.2.2. Positive test results:

- a. Should be reported to the patient and/or guardian via phone call and/or mobile text message (SMS) within 24hrs of result interpretation.
- b. Patients and/or their legal guardian should be provided with infection control guidelines and be informed that they will be contacted by The Public Health and Protection Department for further assessment and management as in (**Appendix 11**).
- c. Facilities are required to provide a daily log of patients that have been contacted to [CovNotify@dha.gov.ae](mailto:CovNotify@dha.gov.ae) - as in (**Appendix 12**).

13.2.3. In circumstances of presumptive positive, the requesting health facility should inform the patient to self-quarantine and repeat the test within 72hrs.

#### **14. STANDARD TEN: NUCLEIC ACID AMPLIFICATION FOR DETECTION OF SARS-COV2 AS POINT OF CARE TEST (POCT)**

14.1. The nucleic acid amplification for detection of SARS-CoV2 as Point of Care test (POCT) can be used in the following settings:

14.1.1. Emergency departments of Hospitals.

14.2. The test should be FDA authorized /Emergency use Authorization.

14.3. Testing should be done for patients with Covid-19 symptoms who are required to be hospitalized.

14.3.1. Testing facility shall follow the algorithm (**Appendix 13**) for detection of SARS-

CoV2 with Nucleic Acid amplification POCT.

14.4. The test should not be used for asymptomatic, mild symptomatic patients or screening.

14.5. Positive (Detected) SARS-CoV2 results must be reported in HASANA.

14.6. Negative results should be confirmed with different authorized or cleared molecular tests (RT-PCR) at an approved Covid-19 testing laboratory by DHA.

14.6.1. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.

14.6.2. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

## 15. STANDARD ELEVEN: ANTIBODY TESTING

15.1. Health Facilities should refrain from using Point Of Care Testing (POCT) or Rapid Test.

15.2. Antibody testing is permitted in COVID-19 treating hospitals only.

15.3. Serologic assays can be carried out only in Clinical Laboratories (standalone or hospital laboratory) approved for RT-PCR meeting the following criteria:

15.3.1. Specificity > 99.5%

15.3.2. FDA approved or have been granted Emergency Use Authorization (EUA)

15.3.3. Kits with CE Mark (European Conformity) are acceptable as long as there is evidence that the kit/analyser have been verified through independent conformity assessment body.

- 15.3.4. Anti-S and Anti-S/RBD IgG titre shall be reported in the international unit of  
BAU/ml.
- 15.4. Clinical laboratories should have the above evidences available and presented upon  
request or visit by HRS.
- 15.5. Serologic testing should not be used for the diagnosis of acute COVID-19 infection nor  
to make decisions about returning persons to the workplace.
- 15.6. Serology test should be used for the below purposes only:
- 15.6.1. Support the diagnosis of COVID-19 illness in late disease presentation with  
negative PCR ( 9-14 days)
- 15.6.2. Support establishing the diagnosis of multisystem hyper-inflammatory  
syndrome in children or cases presenting late in the course of illness
- 15.6.3. Selection of Convalescent Plasma (CP) donors for CP therapy
- 15.6.4. Research purposes.
- 15.7. The price for COVID-19 serologic test should be followed as per latest DHA circulars.
- 15.8. Serological test result should not be entered in HASANA.
- 15.9. Serological test result should not be reported as SMS.
- 15.10. Disclaimers at the end of patient reports should be mentioned for both negative and  
positive results as outlined in (**Appendix 14**).
- 15.11. Antibody serology tests for SARS-CoV-2 should not be used as “Immunity passport”  
and eligibility to receive the vaccine.

## 16. STANDARD TWELVE: INFECTIOUS WASTE MANAGEMENT

- 16.1. All approved testing facilities should comply with DHA Infectious Waste Management and Disposal standards.
- 16.2. Approved testing facilities should have a policy for proper disposal of waste including biological and respiratory waste handling and decontaminating surfaces.
- 16.3. Laboratory waste should be disposed through medical waste management company.

## 17. STANDARD THIRTEEN: SAMPLE RETENTION

- 17.1. Negative (not detected) and (presumptive positive) samples should be stored at fridge (2-8°C) for three days before discarded.
- 17.2. Positive (detected) samples should be stored in the clinical labs at -20°C.
- 17.3. High security and safety measures should always be implemented for stored samples.
- 17.4. Samples should be labelled clearly and should include patient details, MRN and demographics.

## REFERENCES

1. Centers for Disease Control and Prevention (2020). Coronavirus Disease 2019 (COVID-19) CDC Diagnostic Test for COVID-19. Available online at:  
<https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html> (accessed on 18/05/2021).
2. Centers for Disease Control and Prevention (2021). Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. Available online at:  
<https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html> (accessed on 18/05/2021).
3. Centers for Disease Control and Prevention (2021). Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Available online at:  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html> (accessed on 18/05/2021).
4. Centers for Disease Control and Prevention (2021). Coronavirus Disease 2019 (COVID-19) SARS-CoV-2 Viral Culturing at CDC. Available online at:  
<https://www.cdc.gov/coronavirus/2019-ncov/lab/grows-virus-cell-culture.html> (accessed on 18/05/2021).
5. Department of Health Abu Dhabi (2020). Circular No. (44) Regarding Compliance with Laboratories Requirements and Additional Guidelines on COVID-19 Test Indeterminate Results.



6. Dubai Health Authority (2020). Circular regarding Standards for Testing Novel Corona Virus COVID -19.
7. Dubai Health Authority (2020). Circular regarding Serological Testing for COVID-19.
8. Covid-19 Command and Control Center (2021). Quarantine and Isolation Guidelines in the Context of Community Transmission of the Novel Coronavirus (COVID-19). January 5, 2021. Available online at:  
<https://www.dha.gov.ae/en/HealthRegulation/Documents/Attachment%204.pdf>  
(accessed on 18/05/2021).
9. NCEMA (2021). National Guidelines for Clinical Management and treatment of COVID-19. February 18, 2021. Available online at:  
<https://www.dha.gov.ae/en/HealthRegulation/Documents/NationalGuidelinesforClinicalManagementandTreatmentofCOVID-19.pdf> (accessed on 18/05/2021).
10. NCEMA (2020). Guidelines for Contact Tracing of COVID-19 Positive Cases. April 21, 2020. Available online at:  
<https://www.dha.gov.ae/en/HealthRegulation/Documents/دليل%20فحص%20المخالطين.pdf> (accessed on 18/05/2021).
11. NCEMA (2020). Guidelines for Management of a suspected case of COVID-19. April 05, (2020) Available online at:  
<https://www.dha.gov.ae/en/HealthRegulation/Documents/Management%20of%20a%20suspected%20case%20of%20COVID-version%204.pdf> (accessed on 18/05/2021).
12. World Health Organization (2020). Rapid communication on the role of the GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region

(2020). Available at: <http://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/publications/2020/rapid-communication-on-the-role-of-the-genexpert-platform-for-rapid-molecular-testing-for-sars-cov-2-in-the-who-european-region-2020> (accessed on 18/05/2021).

13. Public Health Department Santa Clara Valley Health & Hospital Systems (2020). Drive-Through Medicine.

14. World Health Organization (2020). "Immunity passports" in the context of COVID-19. Available online at: <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19> (accessed on 18/05/2020).

## APPENDICES

### APPENDIX 1: TESTING HEALTH FACILITY REGISTRATION TEMPLATE (SAMPLE COLLECTION)

#### EVALUATION CHECKLIST FOR COVID-19 TESTING FACILITIES

Facility Name:				
SL. No:	Criteria	Yes	No	Documents Required
Accreditation/License				
1	International Accreditation			Provide a Copy of certificate
2	Valid DHA License			Provide a copy of DHA facility license.
Qualified personnel				
3	Physician: - DHA License - Infection control training - Training of COVID-19 sample collection			Provide a copy of DHA License & training log
4	HCP: - DHA License - Infection control training - Training of COVID-19 sample collection			Provide a copy of DHA License & training log
5	Infection Control Policy			Provide copy of policy
PPE and Sample Collection				
6	PPE:- Contract(s) with Supplier(s)- Current Inventory - Strategy to Optimize Supply			Provide details and copies of original contracts
7	Swab: - Contract(s) with Supplier(s) - Current Inventory - Strategy to Optimize Supply			Provide details and copies of original contracts
8	Sample Transport Policy			Provide copy of the policy
Testing Strategy				
9	Capacity: - Current capacity per day (test/day) - Planned capacity increase with timeline			Provide Details
10	Send out Lab(s)			Provide details and copies of original contracts
11	Testing Strategy (Onsite/offsite, targeted groups, working hours, contracts...etc)			Provide details and copies of original contracts

Result Reporting			
12	HASANA Facility Account		Provide date of registration and user details (name , designation)
13	HASANA Training		Training log
14	Result Reporting Policy		Provide copy of the policy
<b>Note:</b> DHA will review the above and might request further information from your facility. Physical inspection will be conducted to ensure the accuracy of the provided details.			
<b>For DHA Official Use Only</b>			
<b>Evaluation Report</b>	.....( <b>Facility Name</b> ) has .....( <i>met/not met/partially met</i> ) all the required criteria set by Dubai Health Authority, for performing COVID-19 Testing at their facility.		
<b>Additional Comments if Any:</b>			

## APPENDIX 2: CLINICAL LABS REGISTRATION TEMPLATE

### EVALUATION CHECKLIST FOR COVID-19 CLINICAL LABORATORIES

Laboratory Name: _____				
SL. No:	Criteria	Yes	No	Documents Required
<b>Accreditation/License</b>				
1	International Laboratory Accreditation (CAP and /or ISO15189)			Provide a Copy of certificate
2	Valid DHA License			Provide a copy of DHA facility license
<b>Qualified personnel</b>				
3	Licensed Pathologist with knowledge on interpretation of the Viral PCR test result for Covid-19			Provide a copy of DHA License of the pathologist & CV
4	Competent and adequate technical/clinical manpower			Provide the list of staff working in PCR lab with their license copy & CV
<b>Analyzer &amp; methodology</b>				
5	Analyzers, Equipment, Reagent supplies for RNA extraction and RT-PCR			<ul style="list-style-type: none"> <li>List the Analyzer details (Extraction and RT-PCR) and provide Laboratory SOPs for the same.</li> <li>Provide the Current Inventory list (Stock) of Extraction tests and PCR tests.</li> <li>Mention the analyzer capacity/day here (N# of tests run/day)</li> </ul>
6	Validation records for COVID-19 test			Provide a copy of validation records.
<b>Quality</b>				
7	Internal Quality Control for COVID-19 test, as required			Provide a copy of QC run - Positive/Negative samples, Internal control (IPC)
8	External QC program/Alternative assessment for COVID-19 test or enroll in any such PT program			Provide a copy of External QC/alternative assessment record
<b>Result Reporting</b>				
9	Confirmatory testing for screening			
10	RT-PCR target gene detection			Provide a policy on result interpretation
11	LIS System that can be integrated with HASANA			Provide details
12	TAT for result reporting			Provide policy and/or system generated reporting TAT.

Policy & Documentation				
13	Policy for Sample processing (RNA Extraction), result reporting (Positive, Negative & Inconclusive result)			Please provide a copy of policy/SOP
14	Policy on specimen retention			Please provide a copy of policy
Safety				
15	Biological Safety Cabinet Level II			
16	Adequate space to perform COVID-19 Testing			
17	Availability of adequate safety measures to protect all the staff from COVID-19 testing (PPE, safety & infection control training, waste management)			<ul style="list-style-type: none"> <li>List the PPE's and provide the current inventory (stock) list.</li> <li>Infection control training log.</li> <li>Waste management policy.</li> </ul>
18	Adequate Engineering controls and Facility design to perform COVID-19 testing (biological safety level II, testing certificate of BSC with HEPA filter change annually and/or negative pressure room)			Provide a copy of annual testing record with change of HEPA filter document
Sample Transport				
19	Sample Transport Policy			Provide the policy
<b>Note:</b> DHA will review the above and might request further information from your facility. Physical inspection will be conducted to ensure the accuracy of the provided details.				
For DHA Official Use Only				
<b>Evaluation Report</b>	.....(Laboratory Name) has .....(met/not met/partially met) all the required criteria set by Dubai Health Authority, for performing COVID-19 Testing at their facility.			
<b>Additional Comments if Any:</b>				

### APPENDIX 3: DRIVE-THROUGH COVID-19 TESTING REGISTRATION TEMPLATE

#### EVALUATION CHECKLIST FOR DRIVE-THROUGH COVID-19 TESTING

Facility Name:				
No:	Criteria	Yes	No	Documents Required
<b>License</b>				
1	<p>Valid DHA License:</p> <ul style="list-style-type: none"> <li>Online application through Sheryan, for COVID Swabbing “Add-on Drive through service”.</li> </ul>			<ul style="list-style-type: none"> <li>Official proposal letter.</li> <li>Target group.</li> <li>Location.</li> <li>Copy of authorization / approval from other authorities, if available.                             <ul style="list-style-type: none"> <li>Approval for operation dates and times: DM, RTA, Dubai Police and Civil defense.</li> </ul> </li> <li>Setup and Infrastructure details (<i>Layout details</i>).</li> <li>Information on maintenance of medical record.</li> <li>Copy of facility license and professionals licenses.</li> </ul>
<b>Qualified personnel</b>				
2	<p>Administration staff/Coordinator staff: 1 per shift.</p> <p>AN/RN/Physician for triaging: 1 per testing line per shift.</p> <p>Screening (testing): 1 HCP per testing line per shift</p> <p>Shift supervisor: 1 per shift.</p> <p>Security Officer: 1 per shift</p>			<ul style="list-style-type: none"> <li>Provide a copy of DHA License for healthcare professionals.</li> <li>Infection control training.</li> <li>Training of COVID-19 sample collection</li> <li>Staffing details: admin, security, coordinators, HCP details who will provide the service, training etc.</li> <li>Staff support equipment.</li> </ul>

Infection Control			
3	<p>Safety protocols &amp; infection control measures.</p> <ul style="list-style-type: none"> <li>Hands washing basin / Hand sanitizer distributed throughout all stations.</li> </ul>		<ul style="list-style-type: none"> <li>Infection Control Policy.</li> </ul>
Design Requirements			
4	<ul style="list-style-type: none"> <li>Open area.</li> <li>Proper ventilation system.</li> <li>One-way passage for vehicles with entrance separate from exit.</li> <li>Divided into stations for parking, registration, and sample collection.</li> <li>Vehicles queue in lanes and pass through a set of designated testing stations.</li> <li>Area structure considerations to accommodate the anticipated influx of patient vehicles.</li> </ul>		<p>Provide the design plan with all necessary information.</p>
Facility Operations			
5	<p>Timing - As per the allowed time of operation and manpower capacity</p>		<p>Operational details and standards including sample collection, storing and transportation.</p>
6	<p>Service provided preferably by appointment.</p>		<p>Call Center / Hotline details. Brochures (For testing procedures, how to self-quarantine, infection precautionary measures).</p>
7	<p>Availability of Medical Record</p>		<p>Provide details of the HIS.</p>
Testing Strategy			
8	<p>Current capacity per day (test/day) Planned capacity increase with timeline</p>		<p>Testing capacity details.</p>



9	Send out Lab(s)			Provide details and copies of original contracts
10	Testing Strategy (targeted groups, contracts...etc)			Provide details and copies of original contracts
<b>Result Reporting</b>				
11	HASANA Facility Account Reporting through HASANA			<ul style="list-style-type: none"> <li>Provide date of registration and user details (name , designation)</li> <li>Reporting and communication channels with patients.</li> </ul>
12	HASANA Training			<ul style="list-style-type: none"> <li>Training log</li> </ul>
13	Result Reporting Policy Keep patients informed by SMS, email, phone call			<ul style="list-style-type: none"> <li>Provide copy of the policy</li> </ul>
<b>Note:</b> DHA will review the above and might request further information from your facility. Physical inspection will be conducted to ensure the accuracy of the provided details.				
<b>For DHA Official Use Only</b>				
<b>Evaluation Report</b>	.....( <b>Facility Name</b> ) has .....( <b>met/not met/partially met</b> ) all the required criteria set by Dubai Health Authority, for performing COVID-19 Testing at their facility.			
<b>Additional Comments if Any:</b>				

## APPENDIX 4: COVID-19 TESTING TENT REGISTRATION TEMPLATE

### EVALUATION CHECKLIST FOR COVID-19 TESTING TENTS

Facility Name:				
No:	Criteria	Yes	No	Documents Required
<b>License</b>				
1	Valid DHA License: <ul style="list-style-type: none"> <li>Online application through Sheryan, for COVID Swabbing 'Add-on'.</li> </ul>			<ul style="list-style-type: none"> <li>Layout and picture of the location.</li> <li>Approval from DM, RTA, Dubai Police for operation dates and times &amp; civil defence.</li> <li>Copy of DHA facility license.</li> </ul>
<b>Qualified personnel</b>				
2	- (1) for triaging and (1) for testing per swab collection station per shift. - DHA License - Infection control training - Training of COVID-19 sample collection			Provide a copy of DHA License & swab collection training log.
3	Administration staff/Coordinator staff: 1 per shift. Shift supervisor: 1 per shift. Security Officer: 1 per shift			Provide full personnel details.
<b>Infection Control</b>				
4	Safety protocols & infection control measures. <ul style="list-style-type: none"> <li>Hands washing basin / Hand sanitizer distributed throughout all stations.</li> </ul>			Infection Control Policy.
<b>Design Requirements</b>				
5	Seating arrangement, if any, should ensure sufficient social distancing measures.			Share seating plans and social distancing measures. A policy in place should be available to avoid overcrowding.

6	Sample Storage area.			Provide temperature control unit details.
7	Separate entry & exit.			Provide patient journey plan.
8	Allocate areas for registration and swab collection.			Provide marked plans.
9	Enough car park spaces.			
<b>Facility Management</b>				
10	Sufficient Air circulation System			Provide details
11	Tent operating hours to be displayed/ conveyed to patients (Not less than 12 hours).			Operating hours
<b>Testing Strategy</b>				
12	Capacity: - Current capacity per day (test/day) - Planned capacity increase with timeline			Provide Details
13	Send out Lab(s)			<ul style="list-style-type: none"> <li>• Provide details and copies of original contracts</li> <li>• Provide sample transportation policy</li> </ul>
14	Testing Strategy (targeted groups, contracts...etc)			Provide details and copies of original contracts
<b>Result Reporting</b>				
15	HASANA Facility Account			Provide date of registration and user details (name , designation)
16	HASANA Training			Training log
17	Result Reporting Policy			Provide copy of the policy
<b>Note:</b> DHA will review the above and might request further information from your facility. Physical inspection will be conducted to ensure the accuracy of the provided details.				
<b>For DHA Official Use Only</b>				
<b>Evaluation Report</b>	.....(Facility Name) has .....(met/not met/partially met) all the required criteria set by Dubai Health Authority, for performing COVID-19 Testing at their facility.			
<b>Additional Comments if Any:</b>				

## APPENDIX 5: APPROVED COVID-19 LABS

	Name	Location
1.	Agiomix	Dubai - Al Barsha South 2
2.	Al Jalila Hospital Lab	Dubai- DHCC
3.	Al Zahra Private Hospital	Dubai - Al Barsha
4.	American Hospital	Dubai - Oud Metha
5.	Aster Hospital	Dubai – Al Qusais
6.	CPS Clinical Pathology Services (MenaLab)	Dubai - Al Qouz 4
7.	Eurofins Biomnis	Dubai - Al Bada
8.	Freiburg Medical Laboratory	Dubai - Al Karama
9.	Garhoud Hospital Lab	Dubai - Garhoud
10.	Iranian Hospital Dubai	Dubai - Satwa
11.	Kings College Hospital	Dubai- Al Barsha
12.	Latifa Hospital Virology Lab	Dubai - Oud Metha
13.	Mediclinic City Hospital / Central Laboratory	Dubai- DHCC
14.	Medsol Dubai Medical Laboratory	Dubai - Al Muraqabat
15.	Molecular Biology and Genomics Lab	Dubai - Zabeel
16.	National Reference Laboratory	Dubai - Al Barsha South 2
17.	NMC Royal Hospital	Dubai - DIP
18.	Pure Health	Dubai Airport
19.	Rashid Hospital Covid-19 Laboratory	Dubai – Umm Hurair 2
20.	Scientific Clinical Laboratories (UniLabs)	Dubai - Jumeirah
21.	SRL Diagnostics	Dubai - DHCC
22.	Star Metropolis Clinical Laboratory	Dubai - Al Hamriya
23.	Thumbay Hospital	Dubai - Al Qusais
24.	Viafet Genomic laboratory	Dubai - Al Badaa
25.	York Diagnostic Laboratories	Dubai - JLT

## APPENDIX 6: TESTING PRIORITY

Priority	Criteria
High Priority	<ul style="list-style-type: none"> <li>Hospitalized patients.</li> <li>Health facility workers, workers in congregate living settings, and first responders with symptoms.</li> <li>Residents in long-term care facilities or other congregate living settings with symptoms.</li> <li>Persons identified through public health cluster and selected contact investigations.</li> </ul>
Priority	<ul style="list-style-type: none"> <li>Persons with symptoms of potential COVID-19 infection, including: fever, cough, shortness of breath, chills, muscle pain, new loss of taste or smell, vomiting or diarrhea and/or sore throat.</li> <li>Persons identified through National Guidelines Contact Tracing and Isolation Guidelines.</li> </ul>

## APPENDIX 7: COVID-19 SAMPLE LABELLING

1. Patient information has to be checked to confirm correct labeling and avoid mislabeling.
2. Please avoid handwritten information on labels.
3. Patient swab labels have to be labelled in vertical direction to avoid barcode scanning issue.



4. Sample racks have to be properly labelled with the Screening location information.




5. Arrange the sample tubes in the rack in the same order as the excel sheet (i.e. sample number 1 in position one in the rack).



6. To avoid sample hazard leak and label fading, keep the rack in a zip-lock nylon bag surrounded by absorbent material.




7. To avoid samples shaking, please arrange the samples racks in transport box with ice packs properly.





**APPENDIX 8: COVID-19 FALSE POSITIVE DUE TO CARRY-OVER CONTAMINATION**



### APPENDIX 9: AUTHORIZED RT-PCR KITS FOR SARS-COV2 BY DHA

Sl. No:	PCR PLAT FORM/KIT	TARGETED GENE
1	Perkin Elmer SARS-CoV2	ORF1ab , N gene
2	Roche SARS-CoV2	ORF1ab, N, E
3	Taqpath-Thermofischer	ORF1ab, N , S
4	Sansure BioTech	ORF1ab , N gene
5	UTOP-SEASUN BIOMATERIALS	Orf1ab, N
6	DIA PLEX-SOLGENT	Orf1ab, N
7	Euroimmune-EURORealTime SARS- CoV- 2	ORF1ab, N
8	Seegene Allplex	E, RdRp, N
9	Argene-BioMérieux SARS-COV-2 R-GENE	RdRp, N, E
10	MasterDiagnostica SARS-CoV2	E, N
11	Neoplex Covid 19 Detection Kit-GeneMatrix	RdRp, N
12	Labsystems Diagnostics-Covid 19Real Time Multiplex RT-PCR Kit	ORF1ab, N & E
13	Inbios International	E, N, ORF1b
14	Cepheid -Xpert Omni SARS-CoV-2	N2, E
15	A & D Genetika for SARS-CoV2	ORF 1ab, N

\*Health Facilities should submit the below requirements for approval of new kits through the facility Sheryan account:

- MOHAP registration and classification of the kit in the UAE.
- Supplier/dealer commercial UAE license.
- SARS-CoV2 RT-PCR kit shall detect two or three genes (ORF1ab or RdRP gene shall be one of the genes).
- FDA Approval / EUA.
- Manufacturer letter confirming the ability of the RT-PCR Kit to detect all variants (UK, Brazilian, Indian...etc).
- Validation with DHA lab of 98% Sensitivity and 98% specificity.

APPENDIX 10: INTERPRETATION OF COVID-19 RT-PCR TEST

ORF1ab (Gene) /RdRp (gene)^	N (gene) /S (gene) <sup>§</sup>	E (gene)	IC	Negative Control	Positive Control	RNA Extraction Control (if applicable)	Interpretation
+	+	+	+ / -	-	+	+	SARS-CoV-2 detected
+	+	-	+ / -	-	+	+	SARS-CoV-2 detected
-	+	+	+ / -	-	+	+	SARS-CoV-2 detected
+	-	-	+ / -	-	+	+	SARS-CoV-2 detected
-	-	-	+	-	+	+	SARS-CoV-2 not detected
-	-	+	+ / -	-	+	+	<b>First time sample*</b> : Single E gene detected positive. Repeat on a second platform and if repeatedly still positive as single gene report as: " <b>Presumptive positive. Only one of multiple gene is isolated. Low viral load possible. please repeat sample in 72 -96 hours to document the course of the disease.</b> " If the 3 <sup>rd</sup> order run is still positive for single E gene and patient is asymptomatic, report: " <b>Acute disease unlikely, please correlate clinically.</b> "
-	-	+	+ / -	-	+	+	<b>Second time sample**</b> : Single E gene detected positive with a historical confirmed positive; this patient could be at the end of

							infection period. Report as: <b>"SARS-CoV-2 detected "</b>
-	+	-	+ / -	-	+	+	<p><b>First time sample:</b> Single N or S gene detected positive. Repeat on another platform for confirmation. If still positive will report as <b>"SARS-CoV-2 detected"</b> and if it is negative on the other platform report: <b>Presumptive Positive. "Only one of multiple gene is isolated. Low viral load possible, please repeat sample in 72 hours and correlate clinically."</b></p> <p style="text-align: right;"><b>First time</b></p> <p><b>sample:</b> Single N gene detected positive, however, 2 targets for N gene available within the assay, report as <b>"SARS-CoV-2 detected"</b></p>
+	+	+	+ / -	-	+	+	<p>If any of Orf1ab / RdRp or N gene or S gene or E gene OR combined are showing a signal of amplification in the late cycles of amplification and the RFU is just above the Baseline Threshold cutoff value , It's Presumptive positive and confirm by another Extraction/PCR platform and follow the manufacturer procedure for enhancement of the reaction. If it is still positive report as <b>"SARS-CoV-2 detected"</b>. If confirmatory test is negative, report: <b>"SARS-CoV-2 not detected, repeat test if deemed necessary."</b></p>
-	-	-	-	-	-	+/-	Invalid run
+	+	+	+	+	+	+/-	Invalid run

\*First time sample: No patient history of previous SARS-CoV test done.

\*\*Second time sample: Patient had previous history of SARS-CoV test.

^ RdRp gene is reported to be less sensitive than the other genes due to mismatch in the reverse primers

§ For labs using S gene as SARS-CoV-2 specific gene and E gene follow the same rule of N gene

## APPENDIX 11: SMS TEMPLATE FOR PCR TEST RESULTS

### NEGATIVE

Dear (Patient Name), (registered MRN)

Greetings, your Covid19 PCR test result from (Order date) is Negative, indicating that you are not infected with the virus. Please Stay Safe.

عزيزنا المتعامل (الاسم بحسب المستندات الرسمية) (رقم الملف الطبي)  
يرجى العلم بأن نتيجة فحصك لكوفيد-19 بتاريخ (تاريخ) "سلبية"، بما يفيد بأنك غير مصاب بالفيروس. ابقى امنا.

### POSITIVE

Dear (Name) (MRN)

Your COVID-19 test on (date) reported that your results is "positive", please download the COVID19 -

DXB Smart App to guide you during your isolation period. <https://dxbcovid19.page.link/smart-app>

If you require any kind of support, please call 800DHA.

Wishing you a speedy recovery

عزيزنا المتعامل (الاسم بحسب المستندات الرسمية) (رقم الملف الطبي)  
نتيجة فحصك لفيروس كورونا كوفيد-19 بتاريخ (تاريخ) "إيجابية"، يرجى تحميل تطبيق COVID19 - DXB Smart App  
لدعمكم خلال فترة عزلكم الصحي.

<https://dxbcovid19.page.link/smart-app>

في حال الحاجة إلى المساعدة، الرجاء الاتصال على 800DHA  
مع تمنياتنا لكم بالشفاء العاجل.

### PRESUMPTIVE

Dear (Name) (MRN),

Your COVID-19 test on (Order date), reported that your result is presumptive positive indicating that you could have the virus. Do not worry; please isolate yourself and repeat the test for confirmation after 72 or 96 hours from this test date, click below link for home isolation instructions <https://www.instagram.com/p/B-eg57FAI0R/>

You can call 800588 from 7am until 11pm for all related inquiries and 800342 for any other inquiry. We are here to support you and we wish you a speedy recovery.

عزيزي المتعامل (الاسم بحسب المستندات الرسمية) (رقم الملف الطبي)


يرجى العلم بأن نتيجة فحصك لكوفيد-19 بتاريخ (تاريخ) "إيجابية مفترضة"، مما يفيد باحتمال إصابتك بالفيروس. لا تقلق، يرجى عزل نفسك حالياً وإعادة الاختبار للتأكيد بعد 72 أو 96 ساعة من تاريخ الاختبار هذا. يرجى الضغط هنا  
<https://www.instagram.com/p/B-eoyaFAMob/?igshid=1uua7bfj5ykbh>

للتعرف على إرشادات العزل المنزلي كما يمكنك الاتصال على الرقم 800588 بين الساعة السابعة صباحاً والحادية عشر للرد على استفساراتك بهذا الشأن، وعلى الرقم 800342 للاستفسارات الأخرى. نحن هنا لمساندتك. مع تمنياتنا لكم بالصحة والعافية.

## APPENDIX 12: CALL LOG REPORT TEMPLATE

Facility Name	Patient Name	Guardian Name (if available)	Patient Number (HASANA)	Contact number	Date of Result	Date of Contact	Time of Contact	Name of Staff

**APPENDIX 13: NUCLEIC ACID AMPLIFICATION AS POINT OF CARE TEST (POCT) FOR SARS-COV 2 TEST AT EMERGENCY DEPARTMENT OF HOSPITALS ALGORITHM**



#### APPENDIX 14: DISCLAIMER STATEMENT IN SEROLOGICAL TESTING FOR COVID-19

- **Negative result:**

“This sample does not contain detectable SARS-CoV-2 IgG (or IgG/IgM as applicable) antibodies. This negative result does not rule out SARS-CoV-2 infection. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended.

A negative result may be due to performing the test prior to development of antibodies (1-4 weeks). Rarely, some people who are infected may not develop antibodies. **Serologic results should not be used as the sole basis to diagnose or exclude recent or past SARS-CoV-2 infection.** This assay was performed using (specify platform & technology used)”

This test is not suitable for diagnosis of COVID-19 Infection; and any suspected case should be testing with RT- PCR.

- **Positive result:**

“Results suggest recent or prior infection with SARS-CoV-2 or Vaccination. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. Protective immunity cannot be inferred based on these results and all preventive measures should be maintained. Infrequently, **false positive results may be due to prior infection with other human coronaviruses.** Serologic results should not be used as the sole basis to diagnose or exclude recent or past SARS-CoV-2 infection. This assay was performed using (specify platform & technology used)”.

This test is not suitable for diagnosis of COVID-19 Infection; and any suspected case should be testing with RT- PCR.

Results of antibody testing should be interpreted with caution in immunocompromised patients (immunodeficiency, cancer, transplant, use of biologics, etc.).